Journals / European Journal of Rheumatology / 2022 / Cilt: 9 - Sayı: 1

Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study

Pages
31–35
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Of the overall group, 68 (45%), 33 (22%), 23 (15%), 18 (12%), and 6 (4%) received golimumab, certolizumab, etanercept, adalimumab, and infliximab.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To retrospectively evaluate the effect of anti-tumor necrosis factor-alpha (TNF-α) drugs on hepatic and renal functions in patients with ankylosing spondylitis (AS).
📊
Key Findings & Data:Methods: A total of 148 patients (89 male, 59 female) who were followed up for a minimum duration of 1 year on newly started anti TNF-α therapy were included.
💡
Conclusion & Impact:Results: Of the overall group, 68 (45%), 33 (22%), 23 (15%), 18 (12%), and 6 (4%) received golimumab, certolizumab, etanercept, adalimumab, and infliximab.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To retrospectively evaluate the effect of anti-tumor necrosis factor-alpha (TNF-α) drugs on hepatic and renal functions in patients with ankylosing spondylitis (AS). Methods: A total of 148 patients (89 male, 59 female) who were followed up for a minimum duration of 1 year on newly started anti TNF-α therapy were included. Patients were divided into 5 groups based on the TNF-α treatment received. Initially, pre-treatment BASDAI (Bath Ankylosing Spondylitis Disease Activity) scores and laboratory results were compared between the groups before the treatment. Also, ESR (erythrocyte sedimentation rate), C-reactive protein (CRP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, and creatinine values were compared before treatment and at 3, 6, and 12 months after treatment. Also presence of hematuria and proteinuria was examined. Results: Of the overall group, 68 (45%), 33 (22%), 23 (15%), 18 (12%), and 6 (4%) received golimumab, certolizumab, etanercept, adalimumab, and infliximab. Baseline demographic characteristics, disease activity scores, and laboratory parameters were comparable between the groups (P > .05). There was a significant decline in BASDAI scores from baseline at 12 months (pre-treatment 5.24 ± 0.5, 3.01 ± 0.48 post-treatment at 12 months, P .05). Also, there were no significant changes in mean creatinine levels (P > .05). There were no correlations between disease activity parameters (ESR, CRP, and BASDAI) and hepatic and renal functions (P > .05). Conclusion: No hepatotoxicity or nephrotoxicity were found in association with the use of anti-TNF-α agents over a 1 year period. However, hepatotoxicity and nephrotoxicity are among known adverse effects of these agents. Based on the existing literature data, routine monitoring of patients in terms of potential hepatic and renal toxicity before and after treatment remains a valid recommendation in clinical practice.

🔖

Cite This Article

BALCI, M. A., AKYOL, L. (2022). Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study. European Journal of Rheumatology, Cilt: 9 - Sayı: 1, 31–35. https://ajindex.com/articles/511467

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti- TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005
  2. 20(7):1400-6. [CrossRef] 2. Walker NJ, Zurier RB. Liver abnormalities in rheumatic diseases. Clin Liver Dis. 2002
  3. 6(4): 933-46. [CrossRef] 3. Dominique L. Liver toxicity of TNFalpha antagonists. Joint Bone Spine. 2008
  4. 75(6):636-8. [CrossRef] 4. Koya M, Pichler R, Jefferson JA. Minimal-change disease secondary to etanercept. Clin Kidney J. 2012
  5. 5(5):420-3. [CrossRef] 5. Manganelli R, Manganelli S, Iannaccone S, et al. Management of antirheumatic drugs in kidney failure. G Ital Nefrol. 2015
  6. 32(6):gin/ 32.6.4. 6. Klinkhoff A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs. 2004
  7. 64(12): 1267-83. [CrossRef] 7. Tobon GJ, Cañas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol. 2007
  8. 26(4):578-81. [CrossRef] 8. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006
  9. 65(4):442-52. [CrossRef] 9. Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology. 2015
  10. 23(2-3):71-7. [CrossRef] 10. van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, et al. Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. Clin Rheumatol. 2012
  11. 31(12): 1677-82. [CrossRef] 11. Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010
  12. 69(9): 1612-7. [CrossRef] 12. Capkin E, Karkucak M, Cosar AM, et al. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study. Int J Rheum Dis. 2015
  13. 18(5):548-52. [CrossRef] 13. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017
  14. 76(6):978-91. [CrossRef] 14. Braun J, Kalden JR. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009
  15. 27(4 Suppl. 55):S164-7. 15. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006
  16. 54(7):2136-46. [CrossRef] 16. In